Details of Disease

General Information of Disease (ID: DISAKJKZ)

• Disease Name: Heparin-induced thrombocytopenia
• Synonyms: heparin-associated thrombocytopenia; heparin-induced thrombocytopenia; HIT; HAT; heparin-induced thrombocytopenia (disease); heparin-induced thrombocytopenia type 2
• Disease Class: 3B64: Thrombocytopenia
• Definition: Heparin-induced thrombocytopenia (HIT) is a drug-induced, immune-mediated prothrombotic disorder associated with thrombocytopenia and venous and/or arterial thrombosis.
• Disease Hierarchy:
  DIS2TXP8: Thrombosis
  DISAKJKZ: Heparin-induced thrombocytopenia
• ICD Code:
  ICD-11: ICD-11: 3B64.12
  ICD-10: ICD-10: D69, D69.5
  Expand ICD-11: 3B64.12
  Expand ICD-10: 'D69; 'D69.5
• Disease Identifiers:
  MONDO ID: MONDO_0018048
  UMLS CUI: C0272285
  MedGen ID: 124423
  HPO ID: HP:0011874
  Orphanet ID: 3325
  SNOMED CT ID: 73397007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rivaroxaban	DMQMBZ1	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VLX-1005	DM3M2BX	Phase 2	Small molecule	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 6 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MSR1	TT2TDH9	Limited	Biomarker	[3]
PTPRJ	TTWMKXP	Limited	Genetic Variation	[4]
FCGR2A	TTXT21W	moderate	Biomarker	[5]
GP6	TTTJUVZ	Strong	Biomarker	[6]
HNMT	TT2B6EV	Strong	Genetic Variation	[7]
YES1	TT0SQ8J	Strong	Genetic Variation	[8]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
APBB3	OTNUTR0N	Limited	Biomarker	[3]
SRA1	OTYOGMTG	Limited	Biomarker	[3]
GPR65	OTCF5O4G	Strong	Genetic Variation	[9]
HLA-DRA	OT7KZMP2	Strong	Genetic Variation	[9]
KIR2DS5	OTXLEN11	Strong	Biomarker	[10]

References

• [1] Rivaroxaban FDA Label
• [2] ClinicalTrials.gov (NCT05785819) A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care. U.S.National Institutes of Health.
• [3] HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia.Pathology. 2018 Jun;50(4):426-436. doi: 10.1016/j.pathol.2017.11.089. Epub 2018 Apr 17.
• [4] Risk factors for heparin-induced thrombocytopenia: Focus on Fc receptors.Thromb Haemost. 2016 Oct 28;116(5):799-805. doi: 10.1160/TH16-02-0109. Epub 2016 Jun 30.
• [5] Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcRIIA): a new option in HIT?.Blood Adv. 2019 Dec 10;3(23):4021-4033. doi: 10.1182/bloodadvances.2019000617.
• [6] The platelet Fc receptor, FcRIIa.Immunol Rev. 2015 Nov;268(1):241-52. doi: 10.1111/imr.12370.
• [7] Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities.Allergy. 2011 Jul;66(7):893-902. doi: 10.1111/j.1398-9995.2011.02548.x. Epub 2011 Apr 13.
• [8] Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey.J Clin Apher. 2019 Oct;34(5):545-554. doi: 10.1002/jca.21709. Epub 2019 May 22.
• [9] A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.Thromb Haemost. 2015 Apr;113(4):772-81. doi: 10.1160/TH14-08-0670. Epub 2014 Dec 11.
• [10] Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).Pharmacotherapy. 2017 Sep;37(9):1164-1171. doi: 10.1002/phar.1983. Epub 2017 Sep 4.